Skip to Content

Osmotica Pharmaceuticals plc

Company NameOsmotica Pharmaceuticals plc
Stock SymbolOSMT
Class PeriodOctober 14, 2018 to April 26, 2019
Lead Plaintiff Motion DeadlineApril 26, 2019

On March 27, 2019, after the markets closed, Osmotica announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change. On this news, shares of Osmotica fell $2.74, or nearly 41%, to close at $4.00 on March 28, 2019, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Osmotica Pharmaceuticals plc investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd